Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Clinical trial NCT02396953 · COMPLETED
Trial details
- NCT number
- NCT02396953
- Sponsor
- Ipsen
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2017-11-28
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.